BioRestorative Therapies submits application for new drug targeting degenerative Dsweweisc disease pain: 4 insights Featured

Written by  Megan Wood | Monday, 09 January 2017 22:16
Social sharing

BioRestorative Therapies submitted an Investigational New Drug Application to the FDA.

Here are five insights:


1. The company hopes to receive clearance to test its cell therapy drug in a clinical trial.


2. The therapy, BRTX-100, is intended to treat chronic lower back pain caused by degenerative disc disease.


3. BRTX-100 includes autologous cultured mesenchymal stem cells from a patient's bone marrow.


4. The product is designed for a non-surgical, intradiscal procedure performed in a physician's office.


More articles on spine:
Drs. Kern Singh, Hyun Bae & more: 5 spine surgeons & neurosurgeons recently receiving honors — Jan. 9, 2017
Are infections associated with analgesic steroid paste after spinal decompression? 5 key notes
3 spine surgeons in the headlines — Jan. 6, 2017

Last modified on Thursday, 12 January 2017 20:16
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months